Devonian Health Group, Inc. · TSXV:GSD
Devonian Health — Investor Presentation (January 2025)
36 slides from Devonian Health's investor presentation, Jan 6, 2025
Slide 1: Corporate Presentation
DEVONIAN HEALTH GROUP TSXv – GSD l OTCQB – DVHGF Corporate Presentation
Slide 2: Cautionary Statements
Cautionary Statements This corporate presentation (“Presentation”) has been prepared by DEVONIAN HEALTH GROUP INC. (“DEVONIAN”) formulation of Thykamine in AD and its Phase 2 clinical trial of its twice-a-day formulation of Thykamine in RD and with market information provided by various third-party
Slide 3: Corporate Snapshot
Corporate Snapshot Clinical Stage Biopharmaceutical Company 1 4 Clinical Stage Biopharmaceutical Company Unique, multi-use platform technology with Multiple Clinical milestones expected in 2025-JULY 2026 multiple mechanisms of action impacting several inflammatory biomarkers • Top-line results phase
Slide 4: Experienced Leadership
Experienced Leadership Clinical Stage Biopharmaceutical Company Luc Gregoire CPA, CA Colette Laurin CPA, CA Dr. André P. Boulet, PhD Pierre Montanaro Dr. Daniel Bouthillier, PhD President & CEO CFO Chief Operations Officer President, Altius VP Research Chief Scientific Officer Healthcare Inc. Sipar,
Slide 5: Board of Directors
Board of Directors Clinical Stage Biopharmaceutical Company Executives with extensive pharma and public company experience André Boulet Luc Grégoire CPA, CA David Baker Jean Forcione Ed Dahl Kathryn J. Gregory Louis Flamand PHD Founder & Chairman President & CEO Sipar, LP 5 TSXv – GSD l OTCQB – DVHG
Slide 6: Thykamine
Thykamine • Thylakoid-based active botanical ingredient (ABI) compound • First-In-Class ABI with Demonstrated Anti-Inflammatory, Anti-Oxidative and Immunomodulatory Properties Multiple Indications---1st Target: Atopic Dermatitis (Eczema) Clinically Effective Convenient Dosing Safe, Well Tolerated We
Slide 7: Thykamine: Pipeline Within A Product
Thykamine Clinical story - Pipeline Within A Product Key Focus on Dermatology Indication Preclinical Phase 1 Phase 2 Phase 3 Atopic Dermatitis (Adult – Topical) Atopic Dermatitis (Pediatric – Topical) Hand & Foot Syndrome associated to Chemotherapy Radiodermatitis associated to Radiotherapy Inflamma
Slide 8: Thykamine: Multifunctional Mode of Action
Thykamine : Multifunctional Mode of Action Platform Mechanisms of Action In-vitro and in Human studies have demonstrated: Complex isolated and optimized for clinical applications Anti-inflammatory effects Inhibition of pro-inflammatory cytokines Stimulates anti-inflamatory Synergistic effect of acti
Slide 9: Thykamine: Pipeline in a Product
Thykamine Pipeline in a Product Initial Focus on Dermatological Inflammatory Disorders Primary Secondary Atopic Dermatitis Demonstrated Proof-of- (ECZEMA) Concept in Mild-to-Moderate Ulcerative Colitis Hand & Foot Syndrome associated with Chemotherapy Radiodermatitis associated with Radiotherapy 9 T
Slide 10: Adult Atopic Dermatitis (AD) Phase 2 Trial
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Setting Stage for Phase 3 Trial PRIMARY ENDPOINT Proportion of patients with an IGA score of 0 (clear) or 1 (almost clear) and with at least a 2-grade improvement in IGA score from baseline. POPULATION *Adults with a diagnosis of AD for at least 6 months
Slide 11: Adult Atopic Dermatitis (AD) Phase 2 Trial
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Setting Stage for Phase 3 Trial Proportion of patients achieving Primary Endpoint : IGA 0 or 1 and 2-point Reduction from Baseline 35.0 * 30.8 30.0 * 25.0 23.1 20.0 19.0 % 15.4 15.0 12.1 9.8 10.0 6.7 5.3 5.0 4.0 2.9 2.3 2.9 2.8 0.0 0.0 0.0 0.0 Day 7 Day 1
Slide 12: Adult Atopic Dermatitis (AD) Phase 2 Trial
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Setting Stage for Phase 3 Trial Proportion of patients achieving Secondary Endpoint : IGA 0 or 1 50.0 * 46.2 45.0 40.0 * * 35.9 35.0 33.3 33.3 30.0 26.8 Thykamine also met 25.0 24.2 other significant % Secondary Endpoints: 19.4 20.0 19.0 BSA 15.8 Prur
Slide 13: Significant Improvement in Key Secondary Endpoints by Treatment Group Over Time
Significant Improvement in Key Secondary Endpoints by Treatment Group Over Time %BSA Pruritus a: p ≤ .05 vs baseline b: p ≤ .01 vs baseline c: p ≤ .001vs baseline d: p ≤ .05 vs vehicle e: p ≤.01 vs vehicle DLQI POEM f: p ≤.001 vs vehicle 13 TSXv – GSD l OTCQB – DVHGF 1 Lynde et al. J Drugs Dermatol.
Slide 14: Adult Atopic Dermatitis (AD) Phase 2 Trial
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Generally well-tolerated - Similar rate of adverse events reported for placebo and Thykamine Incidence of AEs, n (%) that were probably, possibly, or definitely related to study medication (safety population) Thykamine Thykamine Thykamine (PUR 0110) (PUR
Slide 15: Competitive Landscape
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Competitive Landscape Competitive landscape vs new biotech products Efficacy rate similar to other new generation drugs % Patients reaching Mechanism of action Clinical development phase Patient population primary endpoint (p<0.05) Thykamine1 Immunomodula
Slide 16: Thykamine for Atopic Dermatitis: Leadership Position Opportunity
Thykamine for Atopic Dermatitis: Leadership Position Opportunity 101 million adults and 103 million children worldwide have AD. And approx. 70% of treated patients do not reach remission1 Unmet Medical Need Atopic Dermatitis Market 2021- • Better tolerability, safety & convenience 20272 • Safer main
Slide 17: Atopic Dermatitis: High Unmet Medical Need
Atopic Dermatitis: High Unmet Medical Need Burden and Unmet Need in Atopic Dermatitis Even with 90%-100% clearer Despite available therapies, goals are not achieved or sustained for skin, itch can still impact a many patients with AD1-5 patient’s life. Topical agents are widely Systemic therapies, t
Slide 18: Thykamine Milestones
Thykamine Milestones Key Anticipated Milestones Within the Next 24 Months 1 Phase 2/3 Pediatric Atopic Dermatitis Top-line results 2 Phase 2 POC Hand & Foot Syndrome Top-line results 3 Radiodermatitis Pivotal study Top-line results 18 TSXv – GSD l OTCQB – DVHGF
Slide 19: Pediatric Development Program
Thykamine Pediatric Development Program
Slide 20: Global Atopic Dermatitis Market Summary
Global Atopic Dermatitis Market Summary 2028 Market value (US $B) Global AD Market $ 25.3B AD Drug Treatment Market $ 19.7B AD Topical Drug Market $ 13.3B AD Mild-to-Moderate Market (80.8% of Topical) $ 10.8B AD Pediatric Market (62,4%) $ 6.7B 20 Source : Global Atopic Dermatitis Treatment Market, -
Slide 21: Pediatric Mild-to-Moderate AD Treatment Landscape
Pediatric Mild-to-Moderate AD Treatment Landscape Patients with atopic dermatitis are at higher risk of multiple autoimmune diseases (1,2): • Alopecia areata, • Asthma • Celiac disease, Atopic eczema is more common in children, often • Crohn’s disease, developing before their first birthday. • Food
Slide 22: Focus on Pediatric Segment
Focus on Pediatric Segment 1 High value, less crowded market 2 Most treatments available can only be used on alternate basis 3 Younger patients (<12 years): underserved within this market 4 Leadership possibility as new therapeutic approach 22 TSXv – GSD l OTCQB – DVHGF
Slide 23: Pediatric AD Treatment Landscape
Pediatric AD Treatment Landscape Topical Corticosteroids Crisaborole topical Ruxolitinib topical cream Tacrolimus 0.03% Pimecrolimus 0.1% ointment 2% (Eucrisa) 1.5% (Opzelura) (Elidel) • Fear and anxiety regarding PDE4 enzyme blocker First topical JAK inhibitor • Calcineurin inhibitor. • Calcineurin
Slide 24: Focus on Pediatric Market Opportunity
Focus on Pediatric Market Opportunity Target approval in pediatric population with mild-to-moderate AD Phase 2/3 clinical study Randomized, double-blind, placebo Multiple drug concentration controlled, multisite clinical trial Targeting 300 patients Treatment duration 12 weeks Study timeline of 18 t
Slide 25: Thykamine for Supportive Care
Thykamine for Supportive Care
Slide 26: Radiodermatitis Associated to Radiotherapy
Radiodermatitis Associated to Radiotherapy (1,2,3) Unmet Medical Need North America, Europe and Australia 50% 90% Large Patient Impact of patients diagnosed with of these patients will develop some • Pain/discomfort cancer will receive degree of radiodermatitis • Patient’s quality of life and well-b
Slide 27: Hand & Foot Syndrome Associated to Chemotherapy
Hand & Foot Syndrome Associated to Chemotherapy Unmet Medical Need Leadership Position Opportunity Large Patient Impact • Hand & Foot syndrome (HFS), is a well- • Pain/discomfort documented adverse effect of numerous • Patient’s quality of life and well-being • May cause diminution of chemotherapeut
Slide 28: IP and Corporate Summary
; 7 IP and Corporate Summary
Slide 29: Intellectual Property Portfolio
Intellectual Property Portfolio U.S. and international Indication Four (4) Trade marks patent estate covering • Extraction / Isolation / stabilization process • Inflammation • Devonian TM • Composition • Cardiovascular • Farm to Pharm TM • Route of Administration (oral; iv; ip; etc.) • Gastrointesti
Slide 30: State-of-the-Art Pharmaceutical Grade (cGMP)
State-of-the-Art Pharmaceutical Grade (cGMP) EXTRACTION FACILITY • North American sourced raw material • 1,625 square meters • Water system upgradable to produce injectables / sterile eye solutions PHARMACEUTICAL GRADE • Facility with custom designed equipment At scale and further scalable • Full
Slide 31: ALTIUS HEALTH CARE INC.
ALTIUS HEALTH CARE INC. • Ultra-Generic Pharmaceutical Distribution Division • Focused on in-licensing original medicines for distribution in Canada • Off-patent products licensed directly from global pharmaceutical companies • Portfolio of 3 products • January 2024 launch of dexlansoprazole • Simpl
Slide 32: Consolidated Results FY 2024
Consolidated Results FY 2024 Devonian Health Group Inc. Consolidated Statements of Net Loss and Comprehensive Loss For the years ended July 31, 2024 and 2023 2024 2023 $ $ Distribution revenues 17,815,509 2,345,389 Operating expenses Cost of sales 11,826,082 1,453,048 Research and development expens
Slide 33: Consolidated Balance Sheet
Consolidated Balance Sheet Devonian Health Group Inc. Interim Consolidated Statements of Financial Position As at October 31, 2024 and July 31, 2024 (Unaudited) October 31, 2024 July 31, 2024 $ $ Assets Current assets Cash and cash equivalents 12,454,995 9,862,511 Accounts receivable (note 4) 8,178,
Slide 34: Consolidated Results
Consolidated Results Devonian Health Group Inc. Interim Consolidated Statements of Net Loss and Comprehensive Loss For the three-month periods ended October 31,2024 and 2023 (Unaudited) October 31 October 31 2024 2023 $ $ Distribution revenues 5,850,933 1,272,520 Operating expenses Cost of sales 4,1
Slide 35: Stock Information
1 Stock Information CAPITAL STRUCTURE Stock Exchanges TSXv: GSD OTCQB: DVHGF TOTAL OUTSTANDING SHARES 148,222,531 Warrants 12,739,868 Stock Options 20,639,547 FULLY DILUTED SHARE CAPITAL 181,601,946 1) As of December 23, 2024 Nearly C$40M raised to date – mostly private sources Base shelf for C$30M
Slide 36: Thank You
Why Invest in Devonian? • Novel multi faceted prescription pharmaceutical • Addressing unmet needs in auto-immune inflammatory diseases • Body of pre-clinical and clinical works supports readiness for phase 3 • Leadership experienced in pharma research, scaling and financing • De-risked by contribut
Devonian Health Group — Investor Presentation (January 2025) on 6ix